Any content you receive is for information purposes only. Always conduct your own research.
*Sponsored
Autonomix Medical, Inc. (NASDAQ: AMIX) Just Landed On The Street Ideas Watchlist This Morning
—Wednesday, September 30, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Get Focused On (AMIX) While It’s Still Early… September 30, 2026 Dear Reader, Our focus this morning is on Autonomix Medical, Inc. (NASDAQ: AMIX) and the technology behind its nerve-sensing platform. With multiple developments surrounding the company at once, (AMIX) is the one name we’re watching today. The global neuromodulation devices market is projected to grow from $7B in 2026 to nearly $14B by 2033, according to Grand View Research, at a compound annual growth rate exceeding 10%. Behind those numbers is a simple clinical reality: physicians still lack reliable tools to precisely identify, target, and confirm treatment of specific nerves during minimally invasive procedures. Nerve ablation — one of the most common interventional approaches to chronic pain — is still performed without real-time neural feedback. Clinicians deliver energy to an approximate area and evaluate results after the fact. That gap between what the procedure aims to do and what the physician can actually verify in the moment represents a genuine unmet clinical need… And it's exactly what Autonomix Medical, Inc. (NASDAQ: AMIX) was designed to address. The company has developed a first-in-class catheter-based microchip sensing array, powered by a proprietary application-specific integrated circuit (ASIC), capable of detecting and differentiating neural signals below 5 microvolts… To frame that: conventional cardiac sensing technologies operate at approximately 100 microvolts. Autonomix's platform works at a resolution roughly 20 times finer — which, according to the company, enables real-time nerve detection through vessel walls at a level no other commercially available device has demonstrated. The sensory microchip sits just 1-2 millimeters from a custom antenna array. That proximity preserves signal integrity because the neural signal only has to travel a few millimeters instead of passing through layers of surrounding tissue. Multi-channel signaling provides 360-degree directional positioning for neuronal targeting… This is a platform designed not just to treat nerves, but to see them — and then confirm the treatment worked before the procedure ends. Autonomix Medical, Inc. (NASDAQ: AMIX) is topping our watchlist this morning—Wednesday, September 30, 2026.
According to Yahoo Finance, (NASDAQ: AMIX) has a float of less than 900K shares listed as available to the public—with a float that small, the potential exists for big moves if demand begins to shift. Analyst Anthony Vendetti at Maxim Group holds a bullish rating and a $42 target on (AMIX), per the firm's latest coverage listing. With shares recently near $3.80, the analyst's target suggests significant upside potential from current levels. What the Proof-of-Concept Data Actually Shows
The most substantive piece of the Autonomix story is the clinical data from its PoC 1 study in pancreatic cancer pain — widely regarded as one of the most severe and treatment-resistant forms of chronic pain in medicine. According to the company's September 2026 corporate presentation, 100% of femoral-access patients (n=16) responded to the transvascular ablation procedure. The pain reduction trajectory is worth examining closely… Mean VAS pain scores dropped 53% at seven days, 59.2% at 4-6 weeks, and 65.6% at three months post-procedure. The clinically accepted threshold for meaningful pain relief is a 20% VAS reduction — Autonomix exceeded that benchmark by more than threefold at every measured interval. At three months, 100% of responding patients reported zero opi-oid use — a finding with broad implications given the ongoing crisis around opi-oid dependence in pain management. Quality of life improved in 77% of responders. No device-related or procedure-related serious adverse events were reported. Subgroup analysis showed clinically meaningful reductions across all disease stages, including Stage 4 patients — several of whom transitioned from severe pain to mild or near-elimination levels. Pain relief onset was observed within 24 hours of the procedure, and results remained consistently positive through every follow-up window, suggesting the therapeutic effect may be durable rather than transient. The company's follow-on PoC 2 study is now expanding the protocol into additional visceral cancers — stomach, liver, and bile duct — along with earlier-stage pancreatic cancer patients, with refined procedural variables designed to inform a future U.S. IDE trial. The expansion beyond a single cancer type is significant because it begins to validate the platform nature of the technology — this is not a single-indication device. The IP and Regulatory Picture
Autonomix Medical, Inc. (NASDAQ: AMIX) holds 120-plus patents issued and pending across its precision neuromodulation platform — and the pace of new grants has been notable in recent months. In August, the USPTO issued U.S. Patent No. 12,433,670, covering systems to sense, map, and selectively target nerves associated with tumors, cancer-related pain, and organ function — with described applications across pancreatic, prostate, breast, colorectal, liver, ovarian, and bone cancers. Later that month, U.S. Patent No. 12,714,780 was granted, broadening protection around feedback-guided neuromodulation and targeted therapy delivery, including neural ablation for cancer pain… The underlying technology traces to applications originally filed in 2012 and 2014, reflecting over a decade of foundational development work. In September, European Patent No. EP 4 233 700 B1 was granted covering autonomic nervous system assessment technologies — extending IP protection across Europe and reinforcing the company's international portfolio strategy. On the regulatory front, the company completed its GLP preclinical study in August 2026, with final histopathology and laboratory analyses supporting safety and performance objectives. CEO Brad Hauser described the GLP completion as "a critical step in our regulatory and clinical development strategy" that "reinforces the positive safety and performance profile we have observed throughout the study." The company is pursuing a Class II De Novo FDA pathway, targeting clearance in 2028, with IDE clinical trials planned for the U.S. ahead of that submission. 
The De Novo route is worth noting — it's a streamlined classification pathway for novel devices that don't have a predicate, and it can be more capital-efficient than a traditional PMA process. The combined addressable market across Autonomix's target indications — pain management, hypertension, and COPD — represents a total combined space exceeding $100B per the company's corporate materials… Who's at the TableThe credibility of the people guiding a development-stage medtech company often matters as much as the technology itself. In September, Autonomix Medical, Inc. (NASDAQ: AMIX) appointed Sandra Cohen Kalter to its Board of Directors — a 20-year veteran of Medtronic who served as Vice President and Chief Regulatory Counsel, overseeing due diligence and integration for more than 27 acquisitions. Her resume includes direct involvement with Medtronic's Symplicity Spyral Renal Denervation system, Evolut TAVR platform, Micra Transcatheter Pacing System, and PulseSelect Pulsed Field Ablation system… That renal denervation experience is particularly relevant to Autonomix's transvascular neuromodulation approach. Meanwhile, Co-Founder and Chief Medical Officer Dr. Robert Schwartz was recently named the 2026 Cardiovascular Tech Forum Lifetime Achievement Award recipient — a recognition of a career that includes 500-plus scientific publications, 200-plus patents, and the co-invention of the Watchman device, which Boston Scientific acquired and grew into a franchise generating over $1B in annual revenue. Multiple members of the leadership team have been involved in prior exits totaling over $3B, including transactions with AbbVie ($550M) and Allergan ($2.4B). And in September, two scientific abstracts were accepted for poster presentation at the CIRSE 2026 Annual Congress in Copenhagen — covering pain mitigation in pancreatic adenocarcinoma and transvascular precision-guided technology. Peer-level scientific engagement of that kind reinforces that the research community is tracking what Autonomix is building. 10 Reasons Why We’re Focused On (AMIX) This Morning—Wednesday, September 30, 2026…
1. First-in-Class Sensing Resolution: The proprietary ASIC-powered microchip detects neural signals below 5 microvolts — roughly 20 times finer than conventional technologies — enabling real-time nerve identification through vessel walls. 
2. Sub-900K Public Float: According to Yahoo Finance, less than 900K shares exist in the public float, the potential exists for big moves if demand begins to shift. 3. 65.6% Pain Reduction at Three Months: Responding femoral-access patients in the PoC 1 pancreatic cancer study achieved a mean VAS reduction more than three times the clinically significant benchmark, with results strengthening at each follow-up interval. 4. Complete Opi-oid Elimination Among Responders: At three months, 100% of responding patients reported zero opi-oid use — a finding with significant clinical implications in the context of widespread opi-oid dependence. 5. PoC 2 Expanding Into Additional Visceral Cancers: The follow-on study is evaluating the platform in stomach, liver, and bile duct cancers alongside earlier-stage pancreatic cases, with refined procedural variables feeding into U.S. IDE trial design. 6. GLP Preclinical Study Completed: The company completed its GLP preclinical study in August 2026, with histopathology and laboratory analyses supporting safety and performance — a required component of the FDA submission package. 7. Three New Patents in 60 Days: Two U.S. patents and one European patent were granted between August and September 2026, adding to a portfolio of 120-plus patents protecting the precision neuromodulation platform across multiple geographies. 8. European IP Footprint Expanding: The grant of EP 4 233 700 B1 strengthens international protection for autonomic nervous system assessment technologies, complementing the company's U.S. patent estate and supporting a global commercialization strategy. 9. Former Medtronic Chief Regulatory Counsel on the Board10: Sandra Cohen Kalter brings 20 years at Medtronic, more than 27 acquisitions, and direct experience with renal denervation and other category-defining platforms — the kind of regulatory and strategic M&A expertise that's rare at this stage. 10. Award-Winning Scientific Leadership and Proven Exit History: CMO Dr. Robert Schwartz — 2026 CTF Lifetime Achievement Award recipient, 500-plus publications, 200-plus patents, co-inventor of the Watchman device — anchors a leadership team with a combined exit history exceeding $3B. Get Focused On (AMIX) While It’s Still Early…
The research here is specific, the milestones are recent, and the people guiding this company bring credentials that are independently verifiable… Autonomix Medical, Inc. (NASDAQ: AMIX) is advancing a precision nerve-sensing and treatment platform with clinical data that has already exceeded established benchmarks, a regulatory path progressing toward FDA submission, and a board that now includes someone who spent two decades evaluating exactly this type of technology at one of the world's largest medtech companies. We have all eyes on (AMIX) this morning. Take a look at (AMIX) while it’s still early.. Sincerely, Paul Prescott
Co-Founder & Managing Editor
Street Ideas Newsletter |
